JMPWA
GRCE

JP Morgan Private Wealth Advisors’s Grace Therapeutics GRCE Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-563
Closed -$28K – 1532
2018
Q1 		$28K Buy
+563
New +$27.8K ﹤0.01% 1268

Other funds holding GRCE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Private Wealth Advisors's GRCE Position: Q2 2018 in Review

JP Morgan Private Wealth Advisors sold out of Grace Therapeutics (GRCE) in Q2 2018, closing a stake of 563 shares — an estimated $28K sold.

JP Morgan Private Wealth Advisors first reported a position in GRCE in Q1 2018 and held it in 1 quarter. The position peaked at $28K in Q1 2018. 13 funds tracked by Wall St. Rank hold GRCE as of Q2 2018.

  • JP Morgan Private Wealth Advisors reported no remaining Grace Therapeutics position as of Q2 2018 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 563 Grace Therapeutics shares in Q2 2018, an estimated $28K.
  • JP Morgan Private Wealth Advisors first reported a position in Grace Therapeutics in Q1 2018 and held it in 1 quarter.
  • JP Morgan Private Wealth Advisors's Grace Therapeutics position peaked at $28K in Q1 2018.
  • 13 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2018.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.